# XmAb819-01 (NCT05433142)

> Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05433142
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Xencor, Inc.
- Conditions: Clear Cell Renal Cell Carcinoma
- Interventions: XmAb819
- Enrollment: 307
- Primary outcome: Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)
- Primary outcome: Incidence of dose limiting toxicities (DLTs)

## Indexed commentary on XmAb819-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=xmab819-01-nct05433142

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05433142", "email": "<work email>"}; the inbox owner confirms by the emailed link.